Topical 0.1% tacrolimus for the treatment of discoid lupus erythematosus and pemphigus erythematosus in dogs.

Topical 0.1% tacrolimus was used for treatment of localized lesions associated with 10 cases of discoid lupus erythematosus (DLE) and two cases of pemphigus erythematosus (PE) either as a sole therapy (n=2) or as an adjunctive treatment (n=10). Eight of 10 dogs with DLE and both dogs with PE were improved following 8 weeks of topical application. In six of the eight dogs that improved, other medications were discontinued. No adverse effects in clinical or laboratory parameters were noted throughout the study.

[1]  T. Olivry,et al.  The ACVD task force on canine atopic dermatitis (XXII): nonsteroidal anti-inflammatory pharmacotherapy. , 2001, Veterinary immunology and immunopathology.

[2]  Koichiro Nakamura,et al.  Safe and Effective Treatment of Refractory Facial Lesions in Atopic Dermatitis Using Topical Tacrolimus following Corticosteroid Discontinuation , 2001, Dermatology.

[3]  H. Dohy,et al.  Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation , 2001, Bone Marrow Transplantation.

[4]  B. Meiser,et al.  Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  S. Sakuma,et al.  Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). , 2001, International immunopharmacology.

[6]  R. Langley,et al.  Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. , 2001, Journal of the American Academy of Dermatology.

[7]  A. Paller,et al.  A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. , 2001, Journal of the American Academy of Dermatology.

[8]  P. Nghiem.  "Topical immunomodulators?": introducing old friends and a new ally, tacrolimus. , 2001, Journal of the American Academy of Dermatology.

[9]  Sewon Kang,et al.  Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. , 2001, Journal of the American Academy of Dermatology.

[10]  A. Fleischer,et al.  Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. , 2001, Journal of the American Academy of Dermatology.

[11]  M. Lahfa,et al.  Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic Dermatitis , 2000 .

[12]  A. Binnington,et al.  Clinical observations of the treatment of canine perianal fistulas with topical tacrolimus in 10 dogs. , 2000, The Canadian veterinary journal = La revue veterinaire canadienne.

[13]  Griffiths,et al.  Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus , 1999, The British journal of dermatology.

[14]  M. Abecassis,et al.  Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. , 1999, Transplantation Proceedings.

[15]  J. Briegel,et al.  Tacrolimus-based immunosuppressive protocols in lung transplantation. , 1999, Transplantation proceedings.

[16]  T. Bieber.  Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. , 1998, The Journal of allergy and clinical immunology.

[17]  P. Autio,et al.  Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. , 1998, The Journal of investigative dermatology.

[18]  Sewon Kang,et al.  Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. , 1998, Journal of the American Academy of Dermatology.

[19]  M. Duddridge,et al.  Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases , 1997, Annals of the rheumatic diseases.

[20]  H. Bismuth,et al.  Study of the correlation between MEIA and ELISA methods for FK 506 determination in liver transplant recipients , 1997, Journal of clinical pharmacy and therapeutics.

[21]  K. Noda,et al.  Distribution and Protein Binding of FK506, a Potent Immunosuppressive Macrolide Lactone, in Human Blood and Its Uptake by Erythrocytes , 1994, The Journal of pharmacy and pharmacology.

[22]  M. Fujita,et al.  Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. , 1993, Nephron.

[23]  A. Oriente,et al.  Anti-inflammatory effect of FK-506 on human skin mast cells. , 1992, The Journal of investigative dermatology.

[24]  R. Rosychuk,et al.  Use of tetracycline and niacinamide for treatment of autoimmune skin disease in 31 dogs. , 1992, Journal of the American Veterinary Medical Association.

[25]  T. Starzl,et al.  Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. , 1991, Transplantation proceedings.

[26]  B. Freed,et al.  THE EFFECTS OF IMMUNOSUPPRESSIVE AGENTS ON IN VITRO PRODUCTION OF HUMAN IMMUNOGLOBULINS , 1991, Transplantation.

[27]  S. Thiru,et al.  Kidney transplantation in the dog receiving FK-506. , 1987, Transplantation proceedings.

[28]  L. Podestá,et al.  Orthotopic liver transplantation in dogs receiving FK-506. , 1987, Transplantation proceedings.

[29]  Zenoble Rd,et al.  Adrenocortical suppression by topically applied corticosteroids in healthy dogs. , 1987 .